Why did 1AD.AX stock jump today?

1AD.AX stock rose on 24 Feb 2026 largely because of renewed investor interest in the AD-214 clinical program and low market capitalisation. Volume of **638,131** shares amplified the move, while upcoming earnings and trial milestones added speculative buying pressure

What is Meyka AI’s grade for 1AD.AX stock?

Meyka AI rates 1AD.AX **72 out of 100** (Grade B+, Suggestion: BUY). The grade blends benchmark, sector, financial growth, metrics, and consensus. Grades are informational, not financial advice

What price can 1AD.AX stock reach in 12 months?

Meyka AI's forecast model projects a **12-month price of A$0.01** for 1AD.AX stock. Versus today’s A$0.004, that implies **150.00%** upside. Forecasts are model-based projections and not guarantees

What are the main risks for 1AD.AX stock investors?

Main risks include clinical trial setbacks, funding dilution, and low liquidity on the ASX. Financials show negative earnings and tight cash metrics, raising the chance of capital raises that could dilute shareholders of 1AD.AX stock

AU Stocks

AdAlta (1AD.AX) rises 33% at close 24 Feb 2026: AD-214 trial drives interest

ByHuzaifa Zahoor February 24, 2026

AdAlta (1AD.AX) jumped 33.33% to A$0.004 at the ASX close on 24 Feb 2026, making it one of today’s top gainers on the Australian market. The 1AD.AX stock move came on volume of 638,131 shares, above typical intraday activity, and follows renewed interest in the company’s clinical-stage lead, AD-214. Investors are reacting to trial progress and tight market capitalisation of A$522,238, which amplifies price moves in this small-cap biotechnology name. We examine why 1AD.AX stock surged, what the data says, and where the shares might head next